Sanuwave Health to Present at Canaccord Genuity Growth Conference
Sanuwave Health (NASDAQ: SNWV), a provider of FDA-approved wound care products, announced that CEO Morgan Frank will present at the 45th Annual Canaccord Genuity Growth Conference. The presentation is scheduled for August 13, 2025, from 9:30 to 9:55 a.m. ET at the InterContinental Hotel in Boston.
Sanuwave specializes in non-invasive medical systems for regenerative medicine, focusing on skin, musculoskeletal tissue, and vascular structure repair. The company's technology portfolio includes patented energy transfer technologies applied in wound healing, orthopedic/spine, aesthetic/cosmetic, and cardiac/endovascular conditions.
Sanuwave Health (NASDAQ: SNWV), fornitore di prodotti per la cura delle ferite approvati dalla FDA, ha annunciato che il CEO Morgan Frank presenter脿 alla 45陋 Conferenza Annuale Canaccord Genuity Growth. La presentazione 猫 prevista per il 13 agosto 2025, dalle 9:30 alle 9:55 ET presso l'InterContinental Hotel di Boston.
Sanuwave 猫 specializzata in sistemi medici non invasivi per la medicina rigenerativa, con un focus sulla riparazione della pelle, dei tessuti muscoloscheletrici e delle strutture vascolari. Il portafoglio tecnologico dell'azienda include tecnologie brevettate di trasferimento energetico applicate nella guarigione delle ferite, in ambito ortopedico/spinale, estetico/cosmetico e in condizioni cardiache/endovascolari.
Sanuwave Health (NASDAQ: SNWV), proveedor de productos para el cuidado de heridas aprobados por la FDA, anunci贸 que el CEO Morgan Frank presentar谩 en la 45陋 Conferencia Anual de Crecimiento Canaccord Genuity. La presentaci贸n est谩 programada para el 13 de agosto de 2025, de 9:30 a 9:55 a.m. ET en el Hotel InterContinental de Boston.
Sanuwave se especializa en sistemas m茅dicos no invasivos para la medicina regenerativa, centr谩ndose en la reparaci贸n de piel, tejido musculoesquel茅tico y estructuras vasculares. La cartera tecnol贸gica de la compa帽铆a incluye tecnolog铆as patentadas de transferencia de energ铆a aplicadas en la cicatrizaci贸n de heridas, ortopedia/columna, est茅tica/cosm茅tica y condiciones card铆acas/endovasculares.
Sanuwave Health (NASDAQ: SNWV)電� FDA 鞀轨澑 靸侅矘 旃橂 鞝滍拡 鞝滉车鞐呾泊搿�, CEO 氇贝 頂勲灜韥皜 鞝�45須� 鞐半 Canaccord Genuity 靹膘灔 旖橅嵓霟办姢鞐愳劀 氚滍憸頃� 鞓堨爼鞛勳潉 氚滍憸頄堨姷雼堧嫟. 氚滍憸電� 2025雲� 8鞗� 13鞚� 鞓れ爠 9鞁� 30攵勲秬韯� 9鞁� 55攵�(霃欕秬鞁滉皠) 氤挫姢韯� 鞚疙劙旎嫲雱儓 順疙厰鞐愳劀 歆勴枆霅╇媹雼�.
Sanuwave電� 頂茧秬, 攴缄敞瓴� 臁办 氚� 順堦磤 甑“ 氤店惮鞐� 欷戩爯鞚� 霊� 鞛儩 鞚橅暀鞖� 牍勳龚鞀� 鞚橂 鞁滌姢韰滌潉 鞝勲鞙茧 頃╇媹雼�. 須岇偓鞚� 旮办垹 韽姼韽措Μ鞓る姅 靸侅矘 旃橃湢, 鞝曧槙鞕戈臣/觳欖稊, 氙胳毄/頇旍灔頀�, 鞁灔/順堦磤 雮� 靸來儨鞐� 鞝侅毄霅橂姅 韸鬼棃氚涭潃 鞐愲剤歆� 鞝勲嫭 旮办垹鞚� 韽暔頃╇媹雼�.
Sanuwave Health (NASDAQ : SNWV), fournisseur de produits de soins des plaies approuv茅s par la FDA, a annonc茅 que le PDG Morgan Frank pr茅sentera lors de la 45e conf茅rence annuelle Canaccord Genuity Growth. La pr茅sentation est pr茅vue le 13 ao没t 2025, de 9h30 脿 9h55 (heure de l'Est) 脿 l'h么tel InterContinental de Boston.
Sanuwave est sp茅cialis茅e dans les syst猫mes m茅dicaux non invasifs pour la m茅decine r茅g茅n茅rative, se concentrant sur la r茅paration de la peau, des tissus musculo-squelettiques et des structures vasculaires. Le portefeuille technologique de l'entreprise comprend des technologies de transfert d'茅nergie brevet茅es appliqu茅es 脿 la cicatrisation des plaies, 脿 l'orthop茅die/colonne vert茅brale, 脿 l'esth茅tique/cosm茅tique et aux affections cardiaques/endovasculaires.
Sanuwave Health (NASDAQ: SNWV), Anbieter von von der FDA zugelassenen Wundversorgungsprodukten, gab bekannt, dass CEO Morgan Frank auf der 45. j盲hrlichen Canaccord Genuity Growth Conference pr盲sentieren wird. Die Pr盲sentation ist f眉r den 13. August 2025 von 9:30 bis 9:55 Uhr ET im InterContinental Hotel in Boston geplant.
Sanuwave spezialisiert sich auf nicht-invasive medizinische Systeme f眉r die regenerative Medizin mit Fokus auf die Reparatur von Haut, muskuloskelettalem Gewebe und Gef盲脽strukturen. Das Technologieportfolio des Unternehmens umfasst patentierte Energietransfertechnologien, die bei der Wundheilung sowie bei orthop盲dischen/Wirbels盲ulenerkrankungen, 盲sthetischen/kosmetischen und kardialen/endovaskul盲ren Anwendungen eingesetzt werden.
- None.
- None.
EDEN PRAIRIE, Minn., July 22, 2025 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (NASDAQ: SNWV), a leading provider of next-generation, FDA-approved wound care products , today announced, that Morgan Frank, Chief Executive Officer, will present at the 45th Annual Canaccord Genuity Growth Conference, being held August 12鈥�13, 2025, at the InterContinental Hotel in Boston, Massachusetts.
Sanuwave鈥檚 group presentation is scheduled for Wednesday, August 13, from 9:30 to 9:55 a.m. ET. In addition to the presentation, Mr. Frank will be available for one-on-one meetings with investors throughout the conference, which can be scheduled through the Canaccord Genuity conference portal.
For additional information, please contact Sanuwave investor relations at 聽.
About Sanuwave
Sanuwave Health is focused on the research, development, and commercialization of its patented, non-invasive and biological response-activating medical systems for the repair and regeneration of skin, musculoskeletal tissue, and vascular structures.
Sanuwave's end-to-end wound care portfolio of regenerative medicine products and product candidates help restore the body's normal healing processes. Sanuwave applies and researches its patented energy transfer technologies in wound healing, orthopedic/spine, aesthetic/cosmetic, and cardiac/endovascular conditions.
Forward-Looking Statements
This press release may contain 鈥渇orward-looking statements鈥� within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements relating to future financial results, production expectations, plans for future business development activities and expectations regarding the impact of changes in tariff rates. Forward-looking statements include all statements that are not statements of historical fact regarding intent, belief or current expectations of the Company, its directors or its officers. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company鈥檚 ability to control. Actual results may differ materially from those projected in the forward-looking statements. Among the key risks, assumptions and factors that may affect operating results, performance and financial condition are risks associated with regulatory oversight, the Company鈥檚 ability to manage its capital resources, competition and the other factors discussed in detail in the Company鈥檚 periodic filings with the Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking statement.
Contact: [email protected]
FAQ
When is Sanuwave Health (SNWV) presenting at the Canaccord Genuity Growth Conference 2025?
Who will represent Sanuwave Health (SNWV) at the Canaccord Genuity Conference?
What products does Sanuwave Health (SNWV) specialize in?
How can investors schedule meetings with Sanuwave Health (SNWV) management?
